Protocol for an Ongoing, Phase 3 Multicenter, Long-Term Extension Study Investigating the Long-Term Safety and Efficacy of Abrocitinib in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis (JADE EXTEND)